期刊
NEPHROLOGY DIALYSIS TRANSPLANTATION
卷 32, 期 2, 页码 248-253出版社
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfw046
关键词
ANCA-associated vasculitis; end-stage renal disease; haemodialysis; kidney transplantation
资金
- Russian Science Foundation [14-15-00947, 2014]
- Cambridge Biomedical Research Centre
- Terumo BCT
- Russian Science Foundation [14-15-00947] Funding Source: Russian Science Foundation
The outcomes in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis have improved significantly over the past decades, although a significant proportion of them still reach end-stage renal disease (ESRD). Renal replacement therapy (RRT) is associated with a relatively low risk of relapsing vasculitis as a result of anti-rejection treatment after kidney transplantation or quiescence of the autoimmune process in haemodialysis patients, but a flare of vasculitis in the latter setting presents a challenge because the treatment is poorly tolerated. There are benefits of rituximab in haemodialysed patients, as it is more steroid sparing in the treatment of extrarenal disease. More favourable outcomes of kidney transplantation compared with haemodialysis support its use as a preferable method of RRT in patients with vasculitis remission or low disease activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据